Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the initial
purchasers of the previously announced offering of the Company’s 2.50%
Convertible Senior Notes due 2021 (the “Notes”) in a private placement
to qualified institutional buyers pursuant to Rule 144A under the
Securities Act of 1933, as amended, have elected to exercise in full
their option to purchase an additional $37.5 million aggregate principal
amount of the Notes.
for Clovis Oncology Announces Exercise in Full by Initial Purchasers of Their Option to Purchase an Additional $37.5 Million Aggregate Principal Amount of the Company’s 2.50% Convertible Senior Notes Due 2021 investment picks